Research Articles

Evaluation of SPf66 malaria vaccine efficacy in Brazil

This paper reports the efficacy results of the randomized, placebo-controlled, field trial of SPf66 malaria vaccine in Costa Marques, Rondonia, Brazil. This region is characterized by the seasonal distribution of Plasmodium falciparum and P. vivax infections, and the recent occupation by migrants from nonendemic areas. A total of 800 individuals of both sexes, ranging in age from seven to 60 years, were included in the study. Of the initial cohort, 572 participants completed the vaccination schedule. Clinical and parasitologic evaluations were obtained by active and passive searches on a periodic basis. The overall protective efficacy against P. falciparum infections was -1.6% (-32.9% to 22.4%), and 14.1% (-17.0% to 36.9%) for the first episode. The overall protective efficacy for P. vivax infections was -19.7% (-44.8% to 1.03%), and -10.8% (-41.1% to 12.8%) for the first episode. No statistical evidence of an overall significant protective effect of SPf66 malaria vaccine against P. falciparum and P. vivax malaria was obtained in this trial.

This article has been cited by other articles:

				C. Valim, M. Mezzetti, J. Maguire, M. Urdaneta, and D. Wypij Estimation of vaccine efficacy in a repeated measures study under heterogeneity of exposure or susceptibility to infection Phil Trans R Soc A, July 13, 2008; 366(1874): 2347 - 2360. [Abstract] [Full Text] [PDF]

				L. Kedzierski, C. G. Black, M. W. Goschnick, A. W. Stowers, and R. L. Coppel Immunization with a Combination of Merozoite Surface Proteins 4/5 and 1 Enhances Protection against Lethal Challenge with Plasmodium yoelii Infect. Immun., December 1, 2002; 70(12): 6606 - 6613. [Abstract] [Full Text] [PDF]